BRPI0917705A2 - composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto - Google Patents

composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto

Info

Publication number
BRPI0917705A2
BRPI0917705A2 BRPI0917705A BRPI0917705A BRPI0917705A2 BR PI0917705 A2 BRPI0917705 A2 BR PI0917705A2 BR PI0917705 A BRPI0917705 A BR PI0917705A BR PI0917705 A BRPI0917705 A BR PI0917705A BR PI0917705 A2 BRPI0917705 A2 BR PI0917705A2
Authority
BR
Brazil
Prior art keywords
compound
prodrug
disease
treating
preventing
Prior art date
Application number
BRPI0917705A
Other languages
English (en)
Portuguese (pt)
Inventor
Haruyuki Nishida
Ikuo Fujimori
Yasuyoshi Arikawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41508823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917705(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0917705A2 publication Critical patent/BRPI0917705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0917705A 2008-08-27 2009-08-26 composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto BRPI0917705A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008218851 2008-08-27
JP2008269099 2008-10-17
PCT/JP2009/065279 WO2010024451A1 (en) 2008-08-27 2009-08-26 Pyrrole compounds

Publications (1)

Publication Number Publication Date
BRPI0917705A2 true BRPI0917705A2 (pt) 2016-02-16

Family

ID=41508823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917705A BRPI0917705A2 (pt) 2008-08-27 2009-08-26 composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto

Country Status (38)

Country Link
US (3) US8969387B2 (cg-RX-API-DMAC7.html)
EP (1) EP2318390B1 (cg-RX-API-DMAC7.html)
JP (1) JP5638515B2 (cg-RX-API-DMAC7.html)
KR (1) KR101629181B1 (cg-RX-API-DMAC7.html)
CN (1) CN102197033B (cg-RX-API-DMAC7.html)
AR (1) AR073136A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009284867B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917705A2 (cg-RX-API-DMAC7.html)
CA (1) CA2735162C (cg-RX-API-DMAC7.html)
CL (1) CL2011000402A1 (cg-RX-API-DMAC7.html)
CO (1) CO6321166A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110169A (cg-RX-API-DMAC7.html)
CY (1) CY1114452T1 (cg-RX-API-DMAC7.html)
DK (1) DK2318390T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000061A (cg-RX-API-DMAC7.html)
EA (1) EA019741B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11010912A (cg-RX-API-DMAC7.html)
ES (1) ES2423289T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20135786B (cg-RX-API-DMAC7.html)
HR (1) HRP20130653T1 (cg-RX-API-DMAC7.html)
IL (1) IL211335A (cg-RX-API-DMAC7.html)
JO (1) JO2871B1 (cg-RX-API-DMAC7.html)
MA (1) MA32647B1 (cg-RX-API-DMAC7.html)
ME (1) ME01598B (cg-RX-API-DMAC7.html)
MX (1) MX2011001955A (cg-RX-API-DMAC7.html)
MY (1) MY152008A (cg-RX-API-DMAC7.html)
NZ (1) NZ591793A (cg-RX-API-DMAC7.html)
PE (2) PE20141174A1 (cg-RX-API-DMAC7.html)
PL (1) PL2318390T3 (cg-RX-API-DMAC7.html)
PT (1) PT2318390E (cg-RX-API-DMAC7.html)
RS (1) RS52872B (cg-RX-API-DMAC7.html)
SI (1) SI2318390T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201300085B (cg-RX-API-DMAC7.html)
TW (1) TWI473798B (cg-RX-API-DMAC7.html)
UA (1) UA105185C2 (cg-RX-API-DMAC7.html)
UY (1) UY32074A (cg-RX-API-DMAC7.html)
WO (1) WO2010024451A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201101774B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2318390T3 (da) * 2008-08-27 2013-07-08 Takeda Pharmaceutical Pyrrolforbindelser
US20110229879A1 (en) * 2010-03-19 2011-09-22 University Of Rochester Methods and compositions for nuclear staining
CN102452979B (zh) * 2010-11-03 2015-04-01 天津药明康德新药开发有限公司 5-氟-3-吡啶磺酰氯的合成方法
CN102863371B (zh) * 2011-07-06 2016-04-13 中国科学院上海有机化学研究所 氟代二氢吡咯或氟代吡咯
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014003199A1 (en) 2012-06-27 2014-01-03 Takeda Pharmaceutical Company Limited Liquid preparations of amines and organic acids stabilized by salts
JP6343600B2 (ja) * 2013-02-28 2018-06-13 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN105367550A (zh) * 2014-08-11 2016-03-02 江苏柯菲平医药股份有限公司 四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用
UY36547A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
UA124663C2 (uk) 2015-07-30 2021-10-27 Такеда Фармасьютікал Компані Лімітед Таблетка
AU2016307233B2 (en) 2015-08-07 2020-12-24 Bayer Cropscience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
CN106430006B (zh) * 2016-08-18 2018-06-12 国网湖南省电力公司带电作业中心 配电线路移动式绝缘登高作业装置及方法
CN108203430A (zh) * 2016-12-16 2018-06-26 天地人和生物科技有限公司 一种新型可逆性质子泵抑制剂及其制备方法和用途
JP7228535B2 (ja) 2017-07-10 2023-02-24 武田薬品工業株式会社 ボノプラザン含有製剤
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN113527536B (zh) * 2020-04-21 2024-03-22 杭州德柯医疗科技有限公司 一种含氟多糖高分子化合物及其制备方法
US11767311B2 (en) * 2020-06-17 2023-09-26 Ildong Pharmaceutical Co., Ltd. Acid secretion inhibitor and use thereof
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN113620930B (zh) * 2021-07-12 2022-08-16 南京烁慧医药科技有限公司 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用
US20250042872A1 (en) * 2021-12-15 2025-02-06 Ildong Pharmaceutical Co., Ltd. Novel salt of 1-sulfonyl pyrrole derivative, method for preparing same, and pharmaceutical composition including same
KR102802551B1 (ko) * 2021-12-15 2025-05-07 유노비아 주식회사 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2031514T3 (es) 1986-08-29 1992-12-16 Pfizer Inc. 2-guanidino-4-ariltiazoles para el tratamiento de ulceras pepticas.
US5128366A (en) 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5331006A (en) 1990-08-31 1994-07-19 Warner-Lambert Company Amino acid analogs as CCK antagonists
WO1992004025A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Amino acid analogs as cck antagonists
WO1993007751A1 (en) 1991-10-18 1993-04-29 Monsanto Company Fungicides for the control of take-all disease of plants
MX9205392A (es) 1991-10-29 1993-04-01 Du Pont Triazolcarbozamidas herbicidas y procedimiento para su obtencion.
JPH06135961A (ja) 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk 新規ジフェニルピロリルフラン誘導体
US5286742A (en) 1992-11-03 1994-02-15 American Cyanamid Company Pyrrole thiocarboxamide insecticidal and acaricidal agents
US5480902A (en) 1993-08-31 1996-01-02 American Cyanamid Company Thienylpyrrole fungicidal agents
JPH08119936A (ja) 1994-10-18 1996-05-14 Fujisawa Pharmaceut Co Ltd 複素環式誘導体
JPH0930967A (ja) 1995-07-17 1997-02-04 Chugai Pharmaceut Co Ltd 抗潰瘍剤
RU2221782C2 (ru) 1996-08-28 2004-01-20 Дзе Проктер Энд Гэмбл Компани Замещенные циклические аминовые ингибиторы металлопротеаз
CZ225699A3 (cs) 1996-12-23 2000-09-13 Du Pont Pharmaceuticals Company Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa
JPH11209344A (ja) 1998-01-26 1999-08-03 Kyowa Hakko Kogyo Co Ltd 含窒素複素環化合物
GB9817548D0 (en) 1998-08-12 1998-10-07 Novartis Ag Organic compounds
DE60020226T2 (de) 1999-03-10 2006-02-02 Shionogi & Co., Ltd. Medizinische zubereitungen mit [2.2.1] und [3.1.1]bicycloskelett die antagonisten für sowohl pgd 2? als auch txa 2? rezeptoren sind
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
AU3783100A (en) 1999-06-14 2000-12-21 Dow Agrosciences Llc Substituted triazoles, imidazoles and pyrazoles as herbicides
ATE309995T1 (de) 1999-08-26 2005-12-15 Aventis Pharma Inc Substituierte (aminoiminomethyl oder aminomethyl) dihydrobenzofurane und benozopyrane
AU2001258784A1 (en) 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
GB0016453D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
CA2460594A1 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
EP1442041A1 (en) 2001-11-08 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
JP2005520792A (ja) 2001-11-22 2005-07-14 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ピロール合成
US20050101657A1 (en) 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
WO2003068738A1 (en) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
WO2003068740A1 (en) 2002-02-14 2003-08-21 Wyeth Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
BR0311707A (pt) 2002-06-13 2005-03-15 Du Pont Composto, composição e método de controle de pelo menos uma praga invertebrada
MXPA05001688A (es) 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
JP2004315511A (ja) 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
WO2004103968A1 (en) 2003-05-26 2004-12-02 Aponetics Ag Sulfopyrroles
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
EP1655284A1 (en) 2004-10-26 2006-05-10 Aponetics AG 2-Phenylsulfopyrroles
UA94424C2 (en) 2005-08-30 2011-05-10 Такеда Фармасьютикал Компани Лимитед 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
EP2005957B1 (en) 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
JP5345140B2 (ja) 2007-09-28 2013-11-20 武田薬品工業株式会社 プロトンポンプ阻害剤としての５員複素環化合物
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
AU2009246167B2 (en) 2008-05-16 2013-08-22 Takeda California, Inc. Glucokinase activators
DK2318390T3 (da) * 2008-08-27 2013-07-08 Takeda Pharmaceutical Pyrrolforbindelser

Also Published As

Publication number Publication date
KR20110071067A (ko) 2011-06-28
AR073136A1 (es) 2010-10-13
JP2012501296A (ja) 2012-01-19
CN102197033A (zh) 2011-09-21
UA105185C2 (uk) 2014-04-25
JP5638515B2 (ja) 2014-12-10
NZ591793A (en) 2012-11-30
CA2735162A1 (en) 2010-03-04
PE20110300A1 (es) 2011-06-16
SI2318390T1 (sl) 2013-08-30
US20100056577A1 (en) 2010-03-04
CN102197033B (zh) 2014-07-16
HK1157756A1 (en) 2012-07-06
TWI473798B (zh) 2015-02-21
US8993598B2 (en) 2015-03-31
GEP20135786B (en) 2013-03-11
CR20110169A (es) 2011-05-16
MX2011001955A (es) 2011-03-29
DK2318390T3 (da) 2013-07-08
AU2009284867B2 (en) 2014-08-28
SMT201300085B (it) 2013-09-06
PT2318390E (pt) 2013-07-10
AU2009284867A2 (en) 2011-04-21
CY1114452T1 (el) 2016-10-05
EA019741B1 (ru) 2014-05-30
EP2318390A1 (en) 2011-05-11
US20140031393A1 (en) 2014-01-30
WO2010024451A1 (en) 2010-03-04
US8969387B2 (en) 2015-03-03
RS52872B (sr) 2013-12-31
PE20141174A1 (es) 2014-09-19
MY152008A (en) 2014-08-15
TW201010993A (en) 2010-03-16
ECSP11010912A (es) 2011-04-29
AU2009284867A1 (en) 2010-03-04
US20110172275A1 (en) 2011-07-14
MA32647B1 (fr) 2011-09-01
EP2318390B1 (en) 2013-05-01
IL211335A0 (en) 2011-04-28
IL211335A (en) 2013-12-31
ES2423289T3 (es) 2013-09-19
ME01598B (me) 2014-09-20
JO2871B1 (en) 2015-03-15
DOP2011000061A (es) 2011-04-15
CL2011000402A1 (es) 2011-07-29
UY32074A (es) 2010-03-26
EA201170384A1 (ru) 2011-10-31
PL2318390T3 (pl) 2013-09-30
CA2735162C (en) 2015-06-23
KR101629181B1 (ko) 2016-06-13
CO6321166A2 (es) 2011-09-20
US8592597B2 (en) 2013-11-26
ZA201101774B (en) 2012-06-27
HRP20130653T1 (en) 2013-08-31

Similar Documents

Publication Publication Date Title
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0917138A2 (pt) composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0822398A2 (pt) Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BRPI0912348A2 (pt) composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]